CYP2D6 Inhibitor Screening Assay, Catalog: MA-0391

Catalog MA-0391

Size 200 wells

Sample Type Samples Containing Drugs, Inhibitors or Ligands (compounds that can interact and affect CYP2D6 activity).

Method of Detection Fluorometric, Ex/Em = 390/468 nm

Assay Type Quantitative

Application A simple, sensitive plate-based fluorometric assay to assess the effect of various compounds on CYP2D6 enzymatic efficiency.

Storage Conditions -20°C

Shipping Temperature Gel Pack

Shelf Life One year from the date of delivery

CYP2D6, a member of the cytochrome P450 monooxygenase family is a membrane-bound hemeprotein, primarily expressed in the liver with notable concentrations in the substantia nigra and elsewhere in the central nervous system. It is responsible for oxidative metabolism of about 25% of all prescribed drugs. It also activates several prodrugs into their active form, including codeine into morphine, and tamoxifen into endoxifen. CYP2D6 is one of the most polymorphic genes in the human genome with over 170 known allelic variants. Given the broad substrate specificity, knowledge of the enzyme’s activity and sensitivity to inhibitors is of pharmacological importance. AkrivisBio’s CYP2D6 Inhibitor Screening Kit is a simple sensitive way to assess the potency of different compounds towards CYP2D6.